摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(2-Pyridin-4-yl-ethylcarbamoyl)-butyric acid

中文名称
——
中文别名
——
英文名称
4-(2-Pyridin-4-yl-ethylcarbamoyl)-butyric acid
英文别名
5-oxo-5-(2-pyridin-4-ylethylamino)pentanoic acid
4-(2-Pyridin-4-yl-ethylcarbamoyl)-butyric acid化学式
CAS
——
化学式
C12H16N2O3
mdl
MFCD03820599
分子量
236.27
InChiKey
BDKQLLUKXHCLAW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.2
  • 重原子数:
    17
  • 可旋转键数:
    7
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    79.3
  • 氢给体数:
    2
  • 氢受体数:
    4

文献信息

  • Tetracyclic Anthraquinone Derivatives
    申请人:Tianjin Hemay Bio-Tech Co., Ltd
    公开号:US20150166595A1
    公开(公告)日:2015-06-18
    Disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , W, n are defined as in the present application.
    公开了一种由式(I)表示的化合物及其药用可接受的盐,其中R1、R2、R3、R4、R5、W、n的定义如本申请中所述。
  • AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES
    申请人:OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES"
    公开号:US20170183318A1
    公开(公告)日:2017-06-29
    The present invention relates to medicine and includes a method for preventing and treating diseases caused by RNA- and DNA-containing viruses, and concomitant diseases, wherein the method comprises the use of an effective amount of compounds of general formula I or pharmaceutically acceptable salts thereof. The invention also relates to methods for preparing said compounds, pharmaceutical compositions for the prevention or treatment of diseases caused by RNA- and DNA-containing viruses, said compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. The invention addresses the object of providing a novel agent effective in the treatment of diseases caused by an RNA-containing virus belonging to the Enterovirus, Metapneumovirus, Pneumovirus, Respirovirus, or Alfa-coronavirus genus, and/or by a DNA-containing virus belonging to the Adenoviridae and/or Herpesviridae family, and in the prevention and treatment of asthma exacerbation, chronic obstructive pulmonary disease, mucoviscidosis, conjunctivitis, gastroenteritis, hepatitis, myocarditis; in the prevention and treatment of rhinorrhea, acute and infectious rhinitis, pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, laryngotracheobronchitis, bronchitis, bronchiolitis, pneumonia, or airway obstructive syndrome.
    本发明涉及医学,包括一种用于预防和治疗由RNA-和DNA-含病毒引起的疾病以及相关疾病的方法,其中该方法包括使用通式I的化合物或其药用可接受盐的有效量。该发明还涉及制备上述化合物的方法,用于预防或治疗由RNA-和DNA-含病毒引起的疾病的药物组合物,该组合物包括通式I的化合物或其药用可接受盐的有效量。该发明解决了提供一种新型药剂的目标,用于治疗属于肠病毒、副呼吸道病毒、呼吸道病毒、呼吸道病毒或阿尔法冠状病毒属的RNA-含病毒引起的疾病,和/或属于腺病毒科和/或疱疹病毒科的DNA-含病毒引起的疾病,并在预防和治疗哮喘急性发作、慢性阻塞性肺疾病、黏液囊病、结膜炎、胃肠炎、肝炎、心肌炎;在预防和治疗流涕、急性和感染性鼻炎、咽炎、鼻咽炎、扁桃体炎、喉炎、喉气管炎、喉气管支气管炎、支气管炎、支气管炎、肺炎或气道梗阻综合征方面具有有效性。
  • AMIDE COMPOUNDS AND METHODS FOR THE PRODUCTION AND USE THEREOF
    申请人:Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises"
    公开号:EP3118211A1
    公开(公告)日:2017-01-18
    The present invention relates to medicine and includes a method for preventing and treating diseases caused by RNA- and DNA-containing viruses, and concomitant diseases, wherein the method comprises the use of an effective amount of compounds of general formula I or pharmaceutically acceptable salts thereof. The invention also relates to methods for preparing said compounds, pharmaceutical compositions for the prevention or treatment of diseases caused by RNA- and DNA-containing viruses, said compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. The invention addresses the object of providing a novel agent effective in the treatment of diseases caused by an RNA-containing virus belonging to the Enterovirus, Metapneumovirus, Pneumovirus, Respirovirus, or Alfa-coronavirus genus, and/or by a DNA-containing virus belonging to the Adenoviridae and/or Herpesviridae family, and in the prevention and treatment of asthma exacerbation, chronic obstructive pulmonary disease, mucoviscidosis, conjunctivitis, gastroenteritis, hepatitis, myocarditis; in the prevention and treatment of rhinorrhea, acute and infectious rhinitis, pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, laryngotracheobronchitis, bronchitis, bronchiolitis, pneumonia, or airway obstructive syndrome.
    本发明涉及医药,包括一种预防和治疗由含RNA和DNA病毒引起的疾病以及伴随疾病的方法,其中该方法包括使用有效量的通式I化合物或其药学上可接受的盐。本发明还涉及制备所述化合物的方法、用于预防或治疗由含 RNA 和 DNA 病毒引起的疾病的药物组合物,所述组合物包含有效量的通式 I 化合物或其药学上可接受的盐。本发明的目的是提供一种新型制剂,有效治疗由肠病毒属、偏肺病毒属、肺炎病毒属、呼吸道病毒属或阿法-冠状病毒属的含 RNA 病毒引起的疾病、和/或属于腺病毒科和/或疱疹病毒科的含 DNA 病毒,以及预防和治疗哮喘加重、慢性阻塞性肺病、粘液粘稠病、结膜炎、肠胃炎、肝炎、心肌炎;预防和治疗鼻炎、急性和感染性鼻炎、咽炎、鼻咽炎、扁桃体炎、喉炎、喉气管炎、喉气管支气管炎、支气管炎、支气管炎、肺炎或气道阻塞综合征。
  • Tetracyclic anthraquinone derivatives
    申请人:TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD.
    公开号:US10294260B2
    公开(公告)日:2019-05-21
    Disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, W, n are defined as in the present application. Also disclosed is a method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound and a salt thereof according to the present application possess good anticancer and/or antitumor activity, and good water solubility and stability, as well as good tolerance in animal bodies. Also disclosed is a process for preparing a compound represented by formula (I) of the present application.
    公开了一种由式 (I) 代表的化合物及其药学上可接受的盐、 其中 R1、R2、R3、R4、R5、W、n 的定义与本申请相同。还公开了一种治疗癌症的方法,包括向有需要的受试者施用治疗有效量的式 (I) 所代表的化合物或其药学上可接受的盐。根据本申请的化合物及其盐具有良好的抗癌和/或抗肿瘤活性、良好的溶性和稳定性,以及在动物体内良好的耐受性。本申请还公开了一种制备式(I)所代表的化合物的工艺。
  • TETRACYCLIC ANTHRAQUINONE DERIVATIVES
    申请人:Tianjin Hemay Bio-Tech Co., Ltd.
    公开号:EP2824108B1
    公开(公告)日:2017-04-19
查看更多